Summary

This article discusses the results of the 18-month follow-up from the Rituximab in ANCA-Associated Vasculitis trial [RAVE; ISRCTN28528813; Stone JH et al. N Engl J Med 2010], which found that one course of treatment with rituximab was noninferior to standard course of therapy (cyclophosphamide followed by azathioprine) for remission-induction of severe antineutrophil cytoplasmic antibody-associated vasculitis.